Background/Aims Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases in recent years. The aim of this study was to evaluate the effects of sitagliptin with and without a synbiotic supplement in the treatment of patients with NAFLD.
Methods In total, 138 NAFLD patients aged 18-60 years were enrolled in the study. Patients were randomized to one of the following treatments for 16 weeks: Group I (n=68), sitagliptin 50 mg daily plus placebo (one capsule per day) or group II (n=70) sitagliptin 50 mg daily plus synbiotic (one capsule per day). Changes in fasting blood glucose (FBS), liver enzymes, lipid profile, and body mass index were compared between the groups.
Results The mean change in FBS with sitagliptin-placebo from baseline was -10.47±5.77 mg/dL, and that with sitagliptin-synbiotic was -13.52±4.16 mg/dL. There was a significant difference between the groups (P<0.001). The mean change in cholesterol (Chol) was -8.34±28.83 mg/dL with sitagliptin-placebo and -21.25±15.50 mg/dL with sitagliptinsynbiotic. There was a significant difference between the two groups (P=0.029). The administration of sitagliptin-placebo induced an increase of 6.13±27.04 mg/dL in low density lipoprotein (LDL), whereas sitagliptin-synbiotic induced a decrease of 14.92±15.85 mg/dL in LDL. A significant difference was observed between the two groups (P<0.001). On the other hand, in the sitagliptin-synbiotic group, there was significant improvement in aspartate aminotransferase (AST) level compared to the sitagliptin-placebo group (P=0.018).
Conclusions Sitagliptin-synbiotic produced greater improvement in FBS, AST, Chol, and LDL compared to sitagliptin alone in patients with NAFLD.
Citations
Citations to this article as recorded by
The efficacy of gut microbiota-regulating drugs on metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis Yi Wang, Jiqi Ouyang, Houyan Zhang, Yaocun Shen, Wenliang Lv PeerJ.2026; 14: e21166. CrossRef
The effect of gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review and network meta-analysis Yijia Song, Sutong Liu, Lihui Zhang, Wenxia Zhao, Yuanmei Qin, Minghao Liu Frontiers in Nutrition.2025;[Epub] CrossRef
The Management of Cardiometabolic Risk in MAFLD: Therapeutic Strategies to Modulate Deranged Metabolism and Cholesterol Levels Annalisa Pezzoli, Ludovico Abenavoli, Marialaura Scarcella, Carlo Rasetti, Gianluca Svegliati Baroni, Jan Tack, Emidio Scarpellini Medicina.2025; 61(3): 387. CrossRef
Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications Farah Abdelhameed, Attia Mustafa, Chris Kite, Lukasz Lagojda, Alexander Dallaway, Nwe Ni Than, Eva Kassi, Ioannis Kyrou, Harpal S. Randeva Livers.2025; 5(1): 11. CrossRef
Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis Minfang Lv, Ghavam Shafagh, Saiting Yu BMC Gastroenterology.2025;[Epub] CrossRef
Gut Microbiota and Liver Health: Meta-Analysis of Bifidobacterium-Containing Probiotics in NAFLD Management Ko-Shih Chang, Wu-Hsien Kuo, Mu-Hsin Chang, Yao Hsiao, Ru-Yin Tsai International Journal of Molecular Sciences.2025; 26(13): 5944. CrossRef
Synbiotics in Alzheimer’s disease: mechanisms, clinical evidence, and therapeutic prospects Yuhua Lin, Rongping Weng, Huayang Pan, Yangbo Hou, Yipeng Sun, Junkai Wen Journal of Translational Medicine.2025;[Epub] CrossRef
Beneficial effects of the probiotics and synbiotics supplementation on anthropometric indices and body composition in adults: A systematic review and meta‐analysis Saeede Saadati, Kaveh Naseri, Omid Asbaghi, Mohsen Yousefi, Elnaz Golalipour, Barbora de Courten Obesity Reviews.2024;[Epub] CrossRef
Roles of Traditional and Next-Generation Probiotics on Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review and Network Meta-Analysis Yuezhi Zhu, Jen Kit Tan, Jia Liu, Jo Aan Goon Antioxidants.2024; 13(3): 329. CrossRef
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies Khamis Al Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Angelo Maria Patti, Khalid Al Waili, Khalid Al Rasadi, Marcello Ciaccio, Manfredi Rizzo Frontiers in Nutrition.2024;[Epub] CrossRef
Optimal probiotic combinations for treating nonalcoholic fatty liver disease: A systematic review and network meta-analysis Yafang Yang, Ligang Yang, Jiale Wu, Jing Hu, Min Wan, Jindi Bie, Jiaxin Li, Da Pan, Guiju Sun, Chao Yang Clinical Nutrition.2024; 43(6): 1224. CrossRef
Impact of Synbiotic Intake on Liver Metabolism in Metabolically Healthy Participants and Its Potential Preventive Effect on Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD): A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial Aakash Mantri, Anika Köhlmoos, Daniela Stephanie Schelski, Waldemar Seel, Birgit Stoffel-Wagner, Peter Krawitz, Peter Stehle, Jens Juul Holst, Bernd Weber, Leonie Koban, Hilke Plassmann, Marie-Christine Simon Nutrients.2024; 16(9): 1300. CrossRef
The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review Azin Vakilpour, Ehsan Amini-Salehi, Arman Soltani Moghadam, Mohammad-Hossein Keivanlou, Negin Letafatkar, Arman Habibi, Mohammad Hashemi, Negar Eslami, Reza Zare, Naeim Norouzi, Hamed Delam, Farahnaz Joukar, Fariborz Mansour-Ghanaei, Soheil Hassanipour, S Nutrition & Diabetes.2024;[Epub] CrossRef
Clinical improvement effect of regulating gut microbiota on metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis of randomized controlled trials Juan Wu, Xiaoyang Chen, Jun Qian, Guochun Li Clinics and Research in Hepatology and Gastroenterology.2024; 48(7): 102397. CrossRef
Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials Youwen Pan, Yafang Yang, Jiale Wu, Haiteng Zhou, Chao Yang BMC Gastroenterology.2024;[Epub] CrossRef
The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: A systematic review and meta-analysis of randomized controlled trials Vali Musazadeh, Kimia Assadian, Fatemeh Rajabi, Amir Hossein Faghfouri, Yosra Soleymani, Zeynab Kavyani, Behnam Najafiyan Pharmacological Research.2024; 208: 107398. CrossRef
Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease Shendong Wang, Junhao Yin, Zhaojun Liu, Xin Liu, Ge Tian, Xijian Xin, Yiming Qin, Xiujing Feng Life Sciences.2024; 359: 123211. CrossRef
Gut microbiota and obesity: an overview of microbiota to microbial-based therapies Elham Sheykhsaran, Amin Abbasi, Hamed Ebrahimzadeh Leylabadlo, Javid Sadeghi, Samaneh Mehri, Fariba Naeimi Mazraeh, Hadi Feizi, Hossein Bannazadeh Baghi Postgraduate Medical Journal.2023; 99(1171): 384. CrossRef
The Crosstalk between Gut Microbiota and Bile Acids Promotes the Development of Non-Alcoholic Fatty Liver Disease Zhonglin Li, Hang Yuan, Huikuan Chu, Ling Yang Microorganisms.2023; 11(8): 2059. CrossRef
Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis Vali Musazadeh, Maryam Mohammadi Anilou, Mahdi Vajdi, Arash Karimi, Sana Sedgh Ahrabi, Parvin Dehghan Frontiers in Nutrition.2023;[Epub] CrossRef
Using synbiotics supplementation to treat hepatic steatosis: A comprehensive meta-analysis of randomized controlled trials Ammar Nojaid, Jason William, Krisanto Tanjaya, Nurpudji Astuti Taslim, Fahrul Nurkolis Human Nutrition & Metabolism.2023; 32: 200194. CrossRef
Role of Probiotics and Gut microbiota in Liver Diseases Safeena Beevi S S, Biju Pottakkat, Sankar Narayanan Asian Journal of Nursing Education and Research.2023; : 157. CrossRef
Effects of Synbiotic-Containing Bacillus coagulans (GBI-30) on the Cardiovascular Status of Patients With Polycystic Ovary Syndrome: A Triple-blinded, Randomized, Placebo-controlled Study Zahra Hariri, Zahra Yari, Sedighe Hoseini, Afsaneh Mehrnami, Khadijeh Abhari, Golbon Sohrab Clinical Therapeutics.2023; 45(10): e193. CrossRef
Benefits of Combining Sonchus brachyotus DC. Extracts and Synbiotics in Alleviating Non-Alcoholic Fatty Liver Disease Wenwu Huang, Boyuan Shen, Xiumei Li, Tongcun Zhang, Xiang Zhou Foods.2023; 12(18): 3393. CrossRef
Protective Effects of Sitagliptin on Streptozotocin-Induced Hepatic Injury in Diabetic Rats: A Possible Mechanisms Qamraa H. Alqahtani, Samiyah Alshehri, Ahlam M. Alhusaini, Wedad S. Sarawi, Sana S. Alqarni, Raessa Mohamed, Meha N. Kumar, Juman Al-Saab, Iman H. Hasan Diseases.2023; 11(4): 184. CrossRef
Inulin as a Clinical Therapeutic Intervention in Metabolic Associated Fatty Liver Disease Varenka Barbero-Becerra, Eva Juárez-Hernández, Norberto C Chávez-Tapia, Misael Uribe Food Reviews International.2022; 38(sup1): 336. CrossRef
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim Clinical and Molecular Hepatology.2022; 28(3): 425. CrossRef
A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C. T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahim Frontiers in Medicine.2022;[Epub] CrossRef
The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis Shudi Li, Jiangkai Liu, Zhen Wang, Fei Duan, Zi Jia, Xinju Chen, Suling Li Frontiers in Public Health.2022;[Epub] CrossRef
Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease Yajie Fu, Yanzhi Zhou, Linhu Shen, Xuewen Li, Haorui Zhang, Yeqi Cui, Ke Zhang, Weiguo Li, Wei-dong Chen, Shizhen Zhao, Yunfu Li, Wenling Ye Frontiers in Pharmacology.2022;[Epub] CrossRef
Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways Olufunto O. Badmus, Sarah A. Hillhouse, Christopher D. Anderson, Terry D. Hinds, David E. Stec Clinical Science.2022; 136(18): 1347. CrossRef
A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease John A. Dougherty, Erenie Guirguis, Krisy-Ann Thornby Annals of Pharmacotherapy.2021; 55(1): 65. CrossRef
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease Erica Jennison, Christopher D. Byrne Clinical and Molecular Hepatology.2021; 27(1): 22. CrossRef
Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets Alvaro Santos-Laso, María Gutiérrez-Larrañaga, Marta Alonso-Peña, Juan M. Medina, Paula Iruzubieta, María Teresa Arias-Loste, Marcos López-Hoyos, Javier Crespo Biomedicines.2021; 10(1): 46. CrossRef
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis Oluyemi Komolafe, Elena Buzzetti, Audrey Linden, Lawrence MJ Best, Angela M Madden, Danielle Roberts, Thomas JG Chase, Dominic Fritche, Suzanne C Freeman, Nicola J Cooper, Alex J Sutton, Elisabeth Jane Milne, Kathy Wright, Chavdar S Pavlov, Brian R Davids Cochrane Database of Systematic Reviews.2021;[Epub] CrossRef
Efficacy of synbiotic supplementation in obesity treatment: A systematic review and meta-analysis of clinical trials Amir Hadi, Kimia Alizadeh, Hossein Hajianfar, Hamed Mohammadi, Maryam Miraghajani Critical Reviews in Food Science and Nutrition.2020; 60(4): 584. CrossRef
Effects of synbiotic consumption on lipid profile: a systematic review and meta-analysis of randomized controlled clinical trials Amir Hadi, Ehsan Ghaedi, Saman Khalesi, Makan Pourmasoumi, Arman Arab European Journal of Nutrition.2020; 59(7): 2857. CrossRef
The Role of Gut Microbiome-Targeted Therapy in Nonalcoholic Fatty Liver Disease Chencheng Xie, Dina Halegoua-DeMarzio Current Hepatology Reports.2020; 19(4): 420. CrossRef
Gut microbiome–targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression Suzanne R Sharpton, Bharat Maraj, Emily Harding-Theobald, Eric Vittinghoff, Norah A Terrault The American Journal of Clinical Nutrition.2019; 110(1): 139. CrossRef
Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Kenneth Cusi Hepatology.2019; 69(6): 2318. CrossRef
A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach Abbas Ali Sangouni, Saeid Ghavamzadeh Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(5): 2917. CrossRef
Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis Yao Tang, Juan Huang, Wen yue Zhang, Si Qin, Yi xuan Yang, Hong Ren, Qin-bing Yang, Huaidong Hu Therapeutic Advances in Gastroenterology.2019;[Epub] CrossRef
Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter? Chencheng Xie, Dina Halegoua-DeMarzio Nutrients.2019; 11(11): 2837. CrossRef
Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone? Yong Kyun Cho Clinical and Molecular Hepatology.2018; 24(3): 299. CrossRef
Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? Matteo Tacelli, Ciro Celsa, Bianca Magro, Aurora Giannetti, Grazia Pennisi, Federica Spatola, Salvatore Petta Pharmaceuticals.2018; 11(4): 121. CrossRef
First
Prev
